

Daxocox 30 mg - Tablet

Authorised

- Enflicoxib

Product identification

Medicine name:

Daxocox 30 mg - Tablet

Active substance:

Enflicoxib

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Enflicoxib

30.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QM01AH95

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , France , Germany , Greece , Hungary , Ireland , Italy , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , United Kingdom (Northern Ireland)

Package description:

Packaging:Blister (Alu), Package_size:20 (4 x 5) tablets
Packaging:Blister (Alu), Package_size:10 (1 x 10) tablets
Packaging:Blister (Alu), Package_size:24 (6 x 4) tablets
Packaging:Blister (Alu), Package_size:12 (3 x 4) tablets
Packaging:Blister (Alu), Package_size:100 (10 x 10) tablets
Packaging:Blister (Alu), Package_size:50 (5 x 10) tablets
Packaging:Blister (Alu), Package_size:4 (1 x 4) tablets
Packaging:Blister (Alu), Package_size:5 (1 x 5) tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Ecuphar NV

Marketing authorisation date:

20/04/2021

Manufacturing sites for batch release:

Lelypharma B.V.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

19/12/2024

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 18/02/2026

[Download](#)

ema-puar-v5354-daxocox-vra0000246340-en.pdf

ema-puar-v5354-daxocox-vra0003g-en.pdf

ema-puar-daxocox-v-5354-par-en.pdf